CA2417489A1 - Methode de reduction de la pression intraoculaire avec des derives d'indole - Google Patents

Methode de reduction de la pression intraoculaire avec des derives d'indole Download PDF

Info

Publication number
CA2417489A1
CA2417489A1 CA002417489A CA2417489A CA2417489A1 CA 2417489 A1 CA2417489 A1 CA 2417489A1 CA 002417489 A CA002417489 A CA 002417489A CA 2417489 A CA2417489 A CA 2417489A CA 2417489 A1 CA2417489 A1 CA 2417489A1
Authority
CA
Canada
Prior art keywords
indol
ethyl
substituted
carbamic acid
acetylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002417489A
Other languages
English (en)
Inventor
Maria A. Peral
Ward M. Peterson
Jesus J. Pintor
Benjamin R. Yerxa
Robert Plourde Jr.
Edward G. Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Complutense de Madrid
Inspire Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200001916A external-priority patent/ES2172415B2/es
Application filed by Individual filed Critical Individual
Publication of CA2417489A1 publication Critical patent/CA2417489A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Abstract

La présente invention concerne une méthode de réduction de la pression intraoculaire par administration de compositions pharmaceutiques contenant des dérivés d'indole. Les compositions pharmaceutiques efficaces de l'invention contiennent des dérivés d'indole et des analogues de la mélatonine des formules (I à IV). Dans une forme de réalisation préférée, la méthode consiste à abaisser la pression intraoculaire avec un 5-(méthoxycarbonylamino)-N-acétyltryptamine (5-MCA-NAT), également connu sous le nom de GR 135531, qui a une durée d'action prolongée et réduit avec une grande efficacité la pression intraoculaire par comparaison avec la mélatonine. L'invention concerne en outre une méthode de traitement de troubles associés à l'hypertension oculaire, et une méthode de traitement de diverses formes du glaucome. La méthode consiste à administrer une dose effective d'une composition pharmaceutique contenant un dérivé d'indole avec ou sans les agents généralement utilisés pour traiter de tels troubles.
CA002417489A 2000-07-28 2001-07-27 Methode de reduction de la pression intraoculaire avec des derives d'indole Abandoned CA2417489A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ES200001916A ES2172415B2 (es) 2000-07-28 2000-07-28 Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
ES200001916 2000-07-28
US27688501P 2001-03-16 2001-03-16
US60/276,885 2001-03-16
PCT/US2001/024220 WO2002009702A2 (fr) 2000-07-28 2001-07-27 Methode de reduction de la pression intraoculaire avec des derives d'indole

Publications (1)

Publication Number Publication Date
CA2417489A1 true CA2417489A1 (fr) 2002-02-07

Family

ID=26156193

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002417489A Abandoned CA2417489A1 (fr) 2000-07-28 2001-07-27 Methode de reduction de la pression intraoculaire avec des derives d'indole

Country Status (9)

Country Link
EP (1) EP1307191A2 (fr)
JP (1) JP2004518612A (fr)
KR (1) KR20030046395A (fr)
CN (1) CN1450896A (fr)
AR (1) AR035651A1 (fr)
AU (1) AU2001280984A1 (fr)
CA (1) CA2417489A1 (fr)
MX (1) MXPA03000729A (fr)
WO (1) WO2002009702A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7084128B2 (en) 2002-01-18 2006-08-01 Inspire Pharmaceuticals, Inc. Method for reducing intraocular pressure
MXPA04009329A (es) 2002-03-26 2005-01-25 Boehringer Ingelheim Pharma Mimeticos de glucocorticoides, metodos para su preparacion, composiciones farmaceuticas y usos de los mismos.
CN1684701B (zh) * 2002-07-30 2012-10-17 奥默罗斯公司 眼科冲洗液及方法
RS20050174A (en) * 2002-08-29 2007-06-04 Boehringer Ingelheim Pharmaceuticals Inc., -3(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
US7795272B2 (en) 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
EP1750740A4 (fr) 2004-05-06 2009-06-10 Molichem Medicines Inc Traitement de maladies et troubles associes aux membranes au moyen de compositions contenant des lantibiotiques
US7479481B2 (en) 2004-05-06 2009-01-20 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
ES2326907T3 (es) 2004-12-27 2009-10-21 Boehringer Ingelheim Pharmaceuticals Inc. Mimeticos de glucocorticoides, metodos para su preparacion, composiciones farmaceuticas y su uso.
CN101547909A (zh) 2006-12-06 2009-09-30 贝林格尔.英格海姆国际有限公司 糖皮质激素模拟物、其制备方法、药物组合物及其用途
AU2008293513B2 (en) 2007-08-28 2013-11-21 Nanotherapeutics, Inc. Method for producing viral vaccines
BRPI0915680A2 (pt) 2008-06-06 2019-09-24 Boehringer Ingelheim Int miméticos de glicocorticoide, métodos de prepará-los, composições farmacêuticas, e usos dos mesmos
AU2010321831B2 (en) * 2009-11-23 2016-07-07 Allergan, Inc. 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof
EP2523669B1 (fr) 2010-01-11 2016-12-07 Inotek Pharmaceuticals Corporation Combinaison, nécessaire et méthode utilisés pour réduire la pression intraoculaire
MX2012010724A (es) 2010-03-26 2012-11-12 Inotek Pharmaceuticals Corp Metodo para reducir la presion intraocular en seres humanos empleando n6-ciclopentiladenosina (cpa), derivados de cpa o profarmacos de los mismos.
NZ627778A (en) 2012-01-26 2017-01-27 Inotek Pharmaceuticals Corp Anhydrous polymorphs of (2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
SG11201506882YA (en) 2013-03-15 2015-09-29 Inotek Pharmaceuticals Corp Ophthalmic formulations
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
AU2019353144B2 (en) 2018-10-05 2023-11-16 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
JP2023539390A (ja) * 2020-09-02 2023-09-13 エンベリック バイオサイエンシズ カナダ インコーポレイテッド ニトロ化サイロシビン誘導体ならびに５－ｈｔ２ａ受容体を調節するためおよび精神障害を処置するためのその使用
WO2023044556A1 (fr) * 2021-09-24 2023-03-30 Enveric Biosciences Canada Inc. Dérivés de psilocybine aminés et procédés d'utilisation
TW202334089A (zh) 2021-11-02 2023-09-01 美商夫雷爾醫療公司 Ｐｐａｒｇ反向激動劑及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654361A (en) * 1986-01-27 1987-03-31 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Method of lowering intraocular pressure using melatonin
AU616907B2 (en) * 1987-08-17 1991-11-14 Whitby Research, Inc. Melatonin analogues
GB9420529D0 (en) * 1994-10-12 1994-11-30 Pfizer Ltd Indoles
FR2737725B1 (fr) * 1995-08-08 1997-10-31 Valentonine Nouveaux derives acyles de la melatonine et d'analogues melatoninergiques, leur procede de preparation et leur utilisation en tant que medicament

Also Published As

Publication number Publication date
WO2002009702A2 (fr) 2002-02-07
AU2001280984A1 (en) 2002-02-13
EP1307191A2 (fr) 2003-05-07
MXPA03000729A (es) 2004-11-01
AR035651A1 (es) 2004-06-23
WO2002009702A8 (fr) 2003-05-08
JP2004518612A (ja) 2004-06-24
WO2002009702A3 (fr) 2002-12-27
KR20030046395A (ko) 2003-06-12
CN1450896A (zh) 2003-10-22

Similar Documents

Publication Publication Date Title
US6730707B2 (en) Method for reducing intraocular pressure using indole derivatives
CA2417489A1 (fr) Methode de reduction de la pression intraoculaire avec des derives d'indole
JP6816180B2 (ja) 眼障害の治療のための組成物および方法
US6277855B1 (en) Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US20050130931A1 (en) Compositions for the treatment of glaucoma or ocular hypertension
US4906467A (en) Novel, long-duration treatment for glaucoma
US6897201B2 (en) Compositions and methods for the treatment of glaucoma or ocular hypertension
JP2007217437A (ja) カリウムチャンネル遮断剤の投与により、哺乳動物の眼圧を降下する方法
EA016227B1 (ru) Способ лечения офтальмологических неоваскулярных расстройств
JPH09508641A (ja) アンギオテンシン▲ｉｉ▼拮抗薬による正常眼圧緑内障の治療
JPH10510289A (ja) 眼圧を降下するためのクロリドチャンネル遮断剤の使用
EA012668B1 (ru) Окулоселективные лекарственные средства и пролекарства
WO1992004008A1 (fr) Composition pour le traitement des douleurs oculaires
US5525601A (en) Composition for treating ocular pain
JP2844109B2 (ja) 眼疾患治療剤
US5196449A (en) Methods and pharmaceutical compositions for the treatment of ophthalmic diseases
US7084128B2 (en) Method for reducing intraocular pressure
WO2003051291A2 (fr) Composes de 5-hydroxy-indole substitues destines au traitement du glaucome
WO2010056710A1 (fr) Compositions et procédés pour traiter des maladies ophtalmiques
KR20100007983A (ko) 녹내장 및 근시 치료용 벤조 [ｇ] 퀴놀린 유도체
Sorbera et al. Bimatoprost
WO1998001099A2 (fr) Methode de traitement d'ischemies de la retine et de glaucomes, utilisant des isomeres r- ou rr- optiquement purs d'agonistes beta-2-adrenergiques
JP2003505499A (ja) 緑内障の治療のための２−アミノテトラリン誘導体
WO2021194959A1 (fr) Traitement de troubles oculaires avec des dérivés de phosphate d'uridine
US4477460A (en) Topical treatment of ocular hypertension

Legal Events

Date Code Title Description
FZDE Dead